Vyome Holdings Appoints Jerry Leonard as Chief Financial Officer to Strengthen Financial Operations and Support Pipeline Development Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage biopharmaceutical company developing differentiated therapies for immuno-inflammatory and rare disease conditions, has appointed experienced financial executive…
Gossamer Bio Completes 1-for-80 Reverse Stock Split to Support Nasdaq Listing Compliance Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease…
OnMed CareStation Gains Momentum as States Deploy $50 Billion Rural Health Transformation Funding As states across the United States transition from planning to implementation of approximately $50 billion in federal Rural Health Transformation Program funding, healthcare leaders are increasingly exploring…
Catalent Completes $4.7 Billion Debt Refinancing to Strengthen Financial Position and Support Long-Term Growth Catalent, Inc., a global contract development and manufacturing organization (CDMO) serving the pharmaceutical, biotechnology and healthcare industries, has successfully completed a major debt refinancing transaction designed…
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split to Support Nasdaq Compliance bioAffinity Technologies, Inc., a biotechnology company developing noninvasive technologies for the detection of early-stage cancer, has announced that it will implement a 1-for-15 reverse stock split of its common…
Sinovac Reports 12.9% Revenue Growth in First Half of 2026 as Overseas Vaccine Business Expands Sinovac Biotech Ltd., a leading biopharmaceutical company in China, has announced the filing of its unaudited financial results for the six months ended June 30,…
Zai Lab and argenx Report Positive Phase 3 Results for VYVGART Hytrulo in Autoimmune Myositis Zai Lab Limited and argenx have announced positive topline results from the ALKIVIA Phase 3 clinical study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in…
Gossamer Bio Reports Second-Quarter 2026 Results and Advances Seralutinib Toward Planned FDA Submission Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on developing and potentially commercializing therapies for pulmonary vascular and respiratory diseases, has announced its financial results for the…
Spruce Biosciences Secures $5.5 Million Strategic Investment to Expand Access to Investigational TA-ERT for Children With Sanfilippo Syndrome Type B Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies for neurological disorders with…
Adagio Medical Reports Second-Quarter 2026 Results as Ventricular Tachycardia Program Advances Toward FDA Review Adagio Medical Holdings, Inc., a medical technology company focused on developing innovative catheter ablation solutions for cardiac arrhythmias, has reported its financial results for the second…
Inocras Raises $31 Million to Accelerate U.S. Expansion of Whole-Genome Sequencing Platform for Precision Oncology Inocras Inc., a bioinformatics-driven precision medicine company specializing in whole-genome sequencing (WGS) and advanced genomic analytics, has announced the successful completion of an oversubscribed $31…
N-Zyme Biomedical Secures $4.6 Million Series A Financing to Advance Phase 2 Clinical Programs for Novel Reflux Disease Therapy N-Zyme Biomedical has successfully completed its Series A financing round, raising approximately US$4.6 million to support the continued clinical development of…